Orthocell Completes First Commercial Sales of Remplir Nerve Repair Device in Canada

MT Newswires Live

04/30

Orthocell (ASX:OCC) has completed first commercial sales of its Remplir nerve repair device in Canada, a milestone in the global rollout of its peripheral nerve reconstruction product, according to a Thursday Australian bourse filing.

The company said Remplir is now approved for sale and generating revenue in Australia, New Zealand, the US, Singapore, Hong Kong, and Canada, with expansion planned into the EU and UK markets following expected approval in the second half of calendar 2026.

Orthocell held more than AU$48 million in cash as at March 31, with no debt, it added.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2631503455"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2631503455\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2631503455?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 12:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2631503455","market":"hk","top_or_hot":-1,"title":"Orthocell Completes First Commercial Sales of Remplir Nerve Repair Device in Canada","media":"MT Newswires Live","content":"<html><body><p> Orthocell (ASX:OCC) has completed first commercial sales of its Remplir nerve repair device in Canada, a milestone in the global rollout of its peripheral nerve reconstruction product, according to a Thursday Australian bourse filing.</p><p>The company said Remplir is now approved for sale and generating revenue in Australia, New Zealand, the US, Singapore, Hong Kong, and Canada, with expansion planned into the EU and UK markets following expected approval in the second half of calendar 2026.</p><p>Orthocell held more than AU$48 million in cash as at March 31, with no debt, it added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orthocell Completes First Commercial Sales of Remplir Nerve Repair Device in Canada</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrthocell Completes First Commercial Sales of Remplir Nerve Repair Device in Canada\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-04-30 12:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Orthocell (ASX:OCC) has completed first commercial sales of its Remplir nerve repair device in Canada, a milestone in the global rollout of its peripheral nerve reconstruction product, according to a Thursday Australian bourse filing.</p><p>The company said Remplir is now approved for sale and generating revenue in Australia, New Zealand, the US, Singapore, Hong Kong, and Canada, with expansion planned into the EU and UK markets following expected approval in the second half of calendar 2026.</p><p>Orthocell held more than AU$48 million in cash as at March 31, with no debt, it added.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCC.AU","symbol_name":"ORTHOCELL LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2631503455","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2631503455","pubTimestamp":1777523461,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Orthocell  has completed first commercial sales of its Remplir nerve repair device in Canada, a milestone in the global rollout of its peripheral nerve reconstruction product, according to a Thursday Australian bourse filing.The company said Remplir is now approved for sale and generating revenue in Australia, New Zealand, the US, Singapore, Hong Kong, and Canada, with expansion planned into the EU and UK markets following expected approval in the second half of calendar 2026.Orthocell held more than AU$48 million in cash as at March 31, with no debt, it added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCC.AU":"ORTHOCELL LTD","BK7067":"生物科技","BK7508":"医药生物股"},"translate_title":"Orthocell在加拿大完成Remplir神经修复装置首次商业销售","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCC.AU":1},"content_text":"Orthocell (ASX:OCC) has completed first commercial sales of its Remplir nerve repair device in Canada, a milestone in the global rollout of its peripheral nerve reconstruction product, according to a Thursday Australian bourse filing.The company said Remplir is now approved for sale and generating revenue in Australia, New Zealand, the US, Singapore, Hong Kong, and Canada, with expansion planned into the EU and UK markets following expected approval in the second half of calendar 2026.Orthocell held more than AU$48 million in cash as at March 31, with no debt, it added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}